Hsbc Holdings PLC Macrogenics Inc Transaction History

Hsbc Holdings PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$3.31 - $18.51 $15,345 - $85,812	-4,636 Reduced 27.7%	12,103 $51,000
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $163,540 - $359,386	16,739 New	16,739 $246,000
Q4 2022 Feb 14, 2023	SELL	$3.34 - $6.98 $7,561 - $15,802	-2,264 Reduced 12.63%	15,655 $105,000
Q3 2022 Nov 14, 2022	BUY	$3.01 - $5.22 $5,821 - $10,095	1,934 Added 12.1%	17,919 $63,000
Q2 2022 Aug 11, 2022	BUY	$2.25 - $9.99 $35,966 - $159,690	15,985 New	15,985 $47,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.